[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:adrenal-gland-pheochromocytoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":116,"states":121},"Adrenal Gland Pheochromocytoma",17,15,[8,16,22,29,35,41,47,54,61,67,73,79,85,91,97,103,110],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07282587","Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:42.501124Z","2026-05-05T02:43:29.477296Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT03206060","Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma\u002F Paraganglioma",[12],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:27.070855Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06427798","Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma\u002FParaganglioma Previously Treated With Systemic Targeted Radioligand Therapy",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.752853Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT00107289","Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma",[12],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:27.512726Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05636618","Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors",[26],"2026-08-26T02:17:03.534765Z","2026-07-05T05:32:16.808808Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT04924075","Belzutifan\u002FMK-6482 for the Treatment of Advanced Pheochromocytoma\u002FParaganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)",[12],"2026-08-26T02:17:01.714035Z","2026-07-05T05:32:16.796442Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT06479811","[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers",[51],"Phase 1","2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.023362Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT05636540","In Vivo PARP-1 Expression With 18F-FluorThanatrace PET\u002FCT in Patients With Pheochromocytoma and Paraganglioma",[58],"Early Phase 1","2026-08-26T02:19:27.519777Z","2026-05-05T02:43:27.634654Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT00004847","Diagnosis of Pheochromocytoma",[51],"2026-08-26T02:19:25.538428Z","2026-05-05T02:35:31.648966Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06503146","18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection",[12],"2026-08-26T02:18:24.494016Z","2026-05-05T02:35:31.918317Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT00001238","Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders",[],"2026-08-26T02:16:34.792807Z","2026-07-05T18:42:10.720145Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT03160274","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions",[],"2026-08-26T02:17:29.353236Z","2026-05-13T02:55:06.109199Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT03050268","Familial Investigations of Childhood Cancer Predisposition",[],"2026-08-26T02:17:18.747857Z","2026-05-13T02:55:06.107926Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT02402244","Project: Every Child for Younger Patients With Cancer",[],"2026-08-26T02:15:53.461103Z","2026-05-13T02:55:06.094469Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06377033","Using the EHR to Advance Genomic Medicine Across a Diverse Health System",[],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:26.987720Z",{"nct_id":104,"title":105,"phases":106,"status":107,"updated_at":108,"content_modified":109},"NCT07661420","211At-MABG in Adults With Advanced Neuroendocrine Cancers",[51],"NOT_YET_RECRUITING","2026-08-26T02:16:57.705506Z","2026-07-05T03:45:20.260334Z",{"nct_id":111,"title":112,"phases":113,"status":107,"updated_at":114,"content_modified":115},"NCT07714551","Zanzalintinib in Unresectable and Progressive MPGGs",[12],"2026-08-26T02:18:06.247899Z","2026-07-24T01:27:14.916149Z",[117],{"biomarker":118,"count":119,"slug":120},"Somatostatin Receptor",4,"somatostatin-receptor",[122,126,130,133,136,139,142,146,149,152,155,158],{"state":123,"count":124,"slug":125},"Maryland",9,"maryland",{"state":127,"count":128,"slug":129},"Pennsylvania",6,"pennsylvania",{"state":131,"count":119,"slug":132},"Michigan","michigan",{"state":134,"count":119,"slug":135},"Missouri","missouri",{"state":137,"count":119,"slug":138},"New York","new-york",{"state":140,"count":119,"slug":141},"Tennessee","tennessee",{"state":143,"count":144,"slug":145},"California",3,"california",{"state":147,"count":144,"slug":148},"Illinois","illinois",{"state":150,"count":144,"slug":151},"Iowa","iowa",{"state":153,"count":144,"slug":154},"Massachusetts","massachusetts",{"state":156,"count":144,"slug":157},"Minnesota","minnesota",{"state":159,"count":144,"slug":160},"Texas","texas"]